{"id":"hcp0605","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HCP0605 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide enhanced efficacy in androgen receptor-driven cancers.","oneSentence":"HCP0605 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:58.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer (CRPC)"},{"name":"Androgen receptor-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT04252872","phase":"PHASE1","title":"Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-08","conditions":"Healthy","enrollment":64},{"nctId":"NCT04039724","phase":"PHASE1","title":"Pharmacokinetics of HCP1305 and Co-administration of HCP0605, HGP0816 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-02","conditions":"Healthy","enrollment":61},{"nctId":"NCT02916602","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-04","conditions":"Hypertension","enrollment":340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["amlodipine, Losartan"],"phase":"phase_3","status":"active","brandName":"HCP0605","genericName":"HCP0605","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP0605 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Androgen receptor-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}